Adicet Bio, Inc. (ACET) stock
Close on Nov 11, 2026Market cap $27.99MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $27.99M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.27
- Dividend yield
- –
- Free cash flow yield
- -287.33%
Fundamentals
- Net income
- -$91.00M
- EPS, diluted
- -$8.56
- Free cash flow
- -$80.43M
- Book value per share
- $9.56
- Diluted shares
- 11M
Trading
- Next earnings
- Mar 11, 2027 (estimated, during market hours)
- Previous close
- $3.00
- Open
- $3.02
- Day's range
- $2.93 – $3.18
- Volume
- 416,466
- Average volume (20 days)
- 225,467
- Beta (5 years)
- 1.66
- 52-week range
- $2.86 – $11.20
- RSI (14 days)
- 19.4
- Volatility (1 year)
- 75.1%
- Relative volume
- 2.28×
- WACC
- 13.2%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACET | S&P 500 | Difference | ACET per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -46.7% | -2.4% | −44.3 pts | ||
| 3 months | -63.7% | -1.2% | −62.5 pts | ||
| Year to date | -64.5% | +12.3% | −76.8 pts | ||
| 1 year | -71.1% | +12.4% | −83.5 pts | ||
| 3 years | -84.4% | +78.8% | −163.2 pts | -46.2% | +21.4% |
| 5 years | -98.0% | +75.2% | −173.2 pts | -54.5% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Adicet Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About Adicet Bio
Pharmaceutical Preparations
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company utilizes donor-derived peripheral blood cells to engineer "off-the-shelf" chimeric antigen receptor (CAR) therapies intended to facilitate durable clinical activity without triggering graft-versus-host immune responses. Its clinical-stage pipeline is led by prulacabtagene leucel (prula-cel), a CAR T cell product targeting CD20 under evaluation for various autoimmune indications, including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis. Additionally, the company advances preclinical programs such as ADI-212, which targets prostate-specific membrane antigen for solid tumors.
Company profile, executives and historyAdicet Bio stock: common questions
What is Adicet Bio's stock price?
ACET closed at $2.99 on Nov 11, 2026, down 0.33% on the day. Over the past 52 weeks it traded between $2.86 and $11.20.
What is Adicet Bio's market cap?
Adicet Bio was worth $27.99M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ACET's P/E ratio?
Adicet Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$8.56), so it has no meaningful P/E ratio.
Does Adicet Bio pay a dividend?
No. Adicet Bio has not paid a cash dividend over the last twelve months.
When does Adicet Bio report earnings next?
Adicet Bio is expected to report Q4 FY2026 results on Mar 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ACET stock performed over the past year?
Including dividends, ACET returned -71.1% over the past year, against +12.4% for the S&P 500.
How many ACET shares are sold short?
0M shares were sold short at the latest FINRA report, 64.22% of the float, or 2.6 days of average trading volume.
Who are Adicet Bio's competitors?
Companies most similar to Adicet Bio by business, industry and size include NKTX, APVO, RNAC, TPST, JBIO.
See a number that looks wrong?